There is a lot of buzz about biosimilars in general and what their impact might be. Biosimilars are also entering the world of hematologic malignancies in the US with rituximab biosimilars approvals. In this interview for Oncology Tube, I discuss their roles, pros, and cons in how physicians treat and approach various hematologic malignancies. At the time of this interview, which took place during the 2019 annual American Society of Hematology (ASH) meeting, I was an EVP and Chief Medical Officer at Aptitude Health.
See full video at Oncology Tube